Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Ojjaara (momelotinib)
- trofinetide
Interactions between your drugs
trofinetide momelotinib
Applies to: trofinetide, Ojjaara (momelotinib)
MONITOR: Coadministration with trofinetide may increase the plasma concentrations of drugs that are substrates of organic anion transporting polypeptide 1B1 (OATP1B1) and/or 1B3 (OATP1B3) via inhibition of these transporters. Clinical and pharmacokinetic data are currently lacking.
MANAGEMENT: Caution is advised if trofinetide is used concomitantly with substrates of OATP1B1 or OATP1B3, particularly sensitive substrates or those with a narrow therapeutic range. The prescribing information for trofinetide recommends avoiding coadministration with OATP1B1/3 substrates for which minimal concentration changes may lead to serious toxicities. If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever trofinetide is added to or withdrawn from therapy. The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.
References (1)
- (2023) "Product Information. Daybue (trofinetide)." Acadia Pharmaceuticals
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Jakafi
Jakafi (ruxolitinib) is used to treat myelofibrosis, polycythemia vera, and graft versus host ...
Vonjo
Vonjo (pacritinib) is used to treat myelofibrosis with low platelet counts (cytopenic ...
Botox
Botox is used to treat chronic migraines, excessive sweating, bladder conditions, eye muscle ...
Inrebic
Inrebic is used to reduce symptoms of myelofibrosis (MF) in adults, such as night sweats, itching ...
Alecensa
Alecensa (alectinib) is an oral kinase inhibitor that may be used to treat certain types of ...
Alunbrig
Alunbrig (brigatinib) is used to treat anaplastic lymphoma kinase-positive (ALK+) metastatic ...
Augtyro
Augtyro (repotrectinib) is a next-generation TKI (Tyrosine Kinase Inhibitor) cancer medicine used ...
Ayvakit
Ayvakit (avapritinib) is a prescription medicine used for the treatment of gastrointestinal stromal ...
Balversa
Balversa (erdafitinib) is an oral kinase inhibitor that may be used to treat adults with locally ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.